Lipofibromatosis-like neural tumor

Summary

Lipofibromatosis-like neural tumor (MONDO:0956985) is a cancer. Molecularly, LMNA::NTRK1 Fusion confers sensitivity to Entrectinib in Lipofibromatosis-like Neural Tumor (CIViC Level C). A subtype of connective tissue neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lipofibromatosis-like neural tumor
Mondo ID	MONDO:0956985
DOID	DOID:0080894
Is cancer (heuristic)	yes

Disease family

This is a subtype of connective tissue neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › connective tissue disorder › connective tissue neoplasm › lipofibromatosis-like neural tumor

Related subtypes (12): cartilage cancer, chondroma, tenosynovial giant cell tumor, dartoic leiomyoma, cholangiolocellular carcinoma, scirrhous adenocarcinoma, angiomyxoma, fibroblastic neoplasm, chondrosarcoma, bone neoplasm, tumor of adipose tissue, solitary fibrous tumor/hemangiopericytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items; also 6 diagnostic, 1 oncogenic.

Molecular subtype	Therapy	Effect	Level	CIViC
LMNA::NTRK1 Fusion	Entrectinib	Sensitivity/Response	CIViC C	EID11578